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Antibody to mouse interferon has proven useful in demonstrating the role of 
endogenous interferon  in  the pathogenesis of different viral diseases  (1-7) and 
in determining to what extent some of the biologic effects of interferon inducers 
are  mediated  by endogenous  interferon  (8).  Recently,  it  has  been  shown  that 
injection of athymic nude mice with antibody to mouse interferon enhanced the 
growth of several xenogeneic transformed cells as well as human prostatic tumor 
cells (9) and hepatonm cells.~  We show herein that antibody to mouse interferon 
markedly enhances the transplantability of a  variety of murine tumors in immu- 
nocompetent mice.  Furthermore,  we have analyzed some of the  experimental 
conditions relative to this phenomenon using two lines of Friend erythroleukemia 
cells (FLC), ') one characterized as interferon-sensitive and the other as interferon- 
resistant (10,  1 1). The results suggest that there may be low levels of endogenous 
interferon in mice that contribute to host defense against transplantable tumors. 
Materials  and  Methods 
Mice.  5-8 wk-old male and female DBA/2, BALB/c and C57B1/6  mice were obtained 
from the pathogen-free breeding colonies of the Institut de Recherches Scientifiques  sur 
le Cancer (Villejuif). 
Tumor Cells.  The following tumor cells were used: 
Cell line  Characteristics  Received from  References 
FLC-745  Friend virus erythroleukemia; inter-  Dr. E. Affabris  (10, 11) 
feron-sensitive line  Rome, Italy 
FLC-3CI-8  Friend virus erythroleukemia; inter-  Dr. E. Affabris  (10, 11) 
feron-resistant line  Rome, Italy 
* Supported by grants from the Richard Lounsbery Foundation and from the Institut National 
de  la Sant~ et de la  Recherche M~dicale (CRL 8t-20-08) and  Centre  National de  la Recherche 
Scientifique (ATP ETATS-UNIS). 
* On leave of absence from the Istituto Superiore di Sanitfi, Rome, Italy. 
i Shouval, D., B. Rager-Zisman, P. C. Quan, B. R. Bloom, D. A. Shafritz, and L. M. Reid. 1983. 
Restriction of tumorigenicity in nude mice of a human hepatoma cell line persistently infected with 
hepatitis B virus. Submitted for publication. 
Abbreviatiolts used in this paper: BSA, bovine serum albumin; FCS, fetal calf serum; FLC, Friend 
erythroleukemia cells; FLV, Friend leukemia virus; Ig, immunoglobulin; i.p., intraperitoneal; NK, 
natural killer; PBS, phosphate-buffered saline; s.c., subcutaneous; SE, standard error. 
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Cell line  Characteristics  Received from  References 
L 121 OR  Methylcholanthrene-induced tumor  Our laboratory 
cell line; interferon-resistant 
RBL5  Rauscher virus lymphoma line  Dr. J.-P. L,~vy, Paris 
France 
EL4  7,12-Dimethylbenz(a)anthracene-  Our laboratory 
induced tumor cell line 
J558  Myeloma IgA, ),1 cell line  Dr. M. Stanislawsky 
IRSC, Villejuif 
MOPC 104  Myeloma IgM, X1 cell line  Dr. M. Stanislawsky 
IRSC, Villejuif 
CGV  Gross virus tumor cell line  Dr. J.-P. L6vy 
Paris, France 
NS 1  Myeloma cell line  Dr. J.-P. L~vy 
Paris, France 
HFL/B  Friend virus erythroleukemia line  Dr. J.-P. L~vy 
Paris, France 
Ehrlich ascites  Spontaneous  Our laboratory 
(12, 13) 
(12) 
(12) 
Tumor cells were either passaged in culture in RPMI medium (Flow, Irvine, Scotland) 
supplemented with 10% fetal calf serum (FCS), or by weekly intraperitoneal  (i.p.) injections 
in syngeneic mice. The different mouse strains are indicated in Table I. 
Quantitative Estimation  of the Number of FLC in the Peritoneal Cavity by Colony Formation in 
Agarose.  Mice were sacrificed and the peritoneal cavity was washed with 3 mi of RPMI 
medium containing 10%  FCS.  The  total  number of viable cells recovered  from each 
mouse was determined by trypan blue dye exclusion. The techniques of preparation of 
agarose and plating of cells have been described (10). After 4 d of incubation at 37°C (in 
a humidified air-5% CO.2 mixture) colonies of FLC were counted using an inverted light 
microscope. The total number of colonies per dish was calculated as previously described 
(14). Cells recovered from the peritoneal cavity of normal mice do not form colonies in 
agarose (14). 
Hvperimmune and Normal Serum Globulins. 
preparations were as follows: 
The source and activities of the different Ig 
Neutralizing titer 
Description  Source  against 4-8 U of  Reference 
mouse all3 interferon 
Anti-mouse interferon globulins: 
Sheep no. 1-7  Our laboratory 
Sheep no. 5A  Our laboratory 
Sheep (NIH)  Research Resources Branch, 
NIH, Bethesda, MD 
Goat D.M.  Dr. E. De Maeyer, Orsay, 
France 
Rabbit serum  Our laboratory 
Control hyperimmune globulins: 
Our laboratory 
Our laboratory 
Our laboratory 
Research Resources Branch, 
NIH, Bethesda, MD 
Sheep no. 11 anti- 
impurities 
Rabbit-anti-L 1210 
cells 
Normal serum globulins: 
Sheep no. 2 
Sheep (NIH) 
Dr. E. De Maeyer, Orsay, 
France 
Goat 
1.6 ×  106  (2) 
2.5 ×  105  (2) 
1.6 ×  105  Catalog no. 
G-024-501- 
568 
6.4 ×  104  (15) 
3.2 x  105 
<10  (2) 
<10 
<10 
<10 
<10 
(2) 
Catalog no. 
G-025-501 - 
568 
(15) TABLE  I 
Effect of Anti-mouse Interferon Globulin on the Survival of Mice Injected with Different Murine 
Tumors 
Strain of  Treatment 
Tumor cell, 
Conditions of  mouse, No. of  Anti-mouse 
cells injected  interferon  Anti-impuri-  Normal serum 
passage  (i.p./mouse)  globulin  ties globulin  globulin  None  p 
DBA/2 
FLC 745,  105  8/8"  8/8 
In vivo  22.1*  24.5 
(21.3-23.0)  (23.9-25.1) 
10 ~  10/10 
27.4 
(26.9-27.9) 
101  10/10 
31.0 
(29.8-32.3) 
lO/lO 
33.2 
(32.6-33.8) 
6/t0 
53.5 
(46.5-62.9) 
8/8 
25.7 
(25.3-26.1) 
DBA/2 
FLC 745,  105  6/6  3/5  4/6 
In vitro  25.6  47.6  50.1 
(24.4-26.9)  (40.6-57.6)  (45.0-56.5) 
FLC-3CL-8,  105  8/8  6/8 
In vitro  21.3  74.6 
(20.5-22.2)  (61.7-90.9) 
C57BL/6 
RBL 5,  106  9/10  2/10 
In vitro  25.5  89.3 
(23.0-28.5)  (77.2-106.0) 
10 5  5/9  0/9 
41.8  --  I 
(34.7-52.6) 
DBA/2 
10 .~  10/10  10/10  10/10 
21.5  26.0  27.0 
(20.7-22.3)  (25.1-27.0)  (25.5-28.7) 
9/9  9/9  8/9 
26.1  30.8  32.2 
(25.6-26.7)  (29.7-31.9)  (30.1-34.7) 
LI210R, 
In vitro 
102 
BALB/c 
MOPC 104,  10 "~  9/9  3/9 
In vivo  31.8  72.3 
(30.9-32.7)  (62.5-85.8) 
BALB/c 
J  558,  2 x  103  11]12  8/12 
In vivo  28.0  41.6 
(26.2-30.1)  (36.8-47.8) 
C57BL/6 
EL 4,  103  12/12  12/12  12/12 
In vivo  23.3  26.0  28.7 
(22.5-24.2)  (24.9-27.1)  (26.5-30.9) 
In these experiments 5-8-wk old male or female mice were used. Mice were injected i.p. with 0.2 
ml of 1:10 dilutions of sheep no.  1-7 anti-mouse interferon globulin; sheep no.  11 anti-impurities 
globulin; sheep no. 2 normal serum globulin; or left untreated.  Mice were injected -2, 0, +7, and 
+ 14 days (tumor cells were inoculated on day 0). Experiments usually were terminated between 3 
and  4  months,  at  which  time  surviving mice  were  autopsied.  Significant differences  in  these 
experiments were observed only between the group of mice injected with anti-interferon globulin 
(underlined) and the control groups. The p values refer to this difference. No significant difference 
was observed between the control groups. 
* Number of mice dead with tumor/Total no. of mice inoculated. 
* Harmonic mean day of death _+ SE. 
p< 0.05. 
u p <  0.01. 
p <  0.001. 
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All sera were decomplemented and extensively absorbed on C-243 cells and on Swiss 
mouse thymocytes and spleen cells as previously described (2). For some experiments sera 
were further absorbed on DBA/2 mouse spleen cells and on a pool of FLC taken from 
mice with  ascites.  The Ig fractions were separated by ammonium sulfate precipitation 
(protein content varied between 20 and 33 mg/ml) and were shown to be devoid of any 
cytotoxicity (2). The anti-mouse interferon a/[3 globulins did not neutralize interferon 3". 
A  sheep  was  immunized  against  the  contaminating  proteins  in  the  partially  purified 
interferon preparations. This serum globulin is referred to as "anti-impurities" (2). The 
hyperimmune rabbit sera were absorbed on murine cells but the Ig fractions were not 
prepared. 
Determinatio, of  l, terfero, i, Various Tissues; and Spleen NK Cell Activity.  The techniques 
•  used to determine the presence of interferon in various tissues have been described (2) as 
well as the techniques used to determine NK cell activity using YAC target cells (16). 
Statistical Analyses.  All data were analyzed by Student's t-test (comparison of harmonic 
mean and slopes of regression lines). 
Results 
Injection of Mice with Anti-interferon Globulins Enhances the Transplantability 
of Several Murine Tumors and Shortens the Survival Time of Tumor-inoculated 
Mice 
The results illustrated in Table I may be summarized as follows: 
Injection of mice with anti-interferon globulin enhanced the transplantability 
of murine  tumor  cells  injected  i.p.  (compared  with  mice  injected  with  anti- 
impurities globulin, normal serum globulin or left untreated) as manifested by a 
markeddecrease in survival time and in some instances an increased percentage 
of tumor-bearing  mice.  (a)  The effect was observed using 6  murine tumors (8 
cell lines) of different origin and in 3 strains of mice. (b) The effect was observed 
in mice injected with a  large or small number of tumor cells. (c) The effect was 
observed in mice injected with tumor cells that had been passaged in vitro or in 
vivo, although the difference was much more pronounced when in vitro passaged 
cells were injected. 
In some tumor systems, however, injection of mice with anti-interferon glob- 
ulin  did  not  affect tumor  transplantability  under  the  experimental  conditions 
used (data not shown). Thus, it failed to affect: (a) the transplantability of in vitro 
passaged 745 FLC injected into allogeneic C57B1/6 mice or BALB/c mice (which 
like DBA/2 mice are H-2d), (b) the growth of three tumor cell lines (CVG, NSI, 
and HFL/B) that had been passaged in vitro and were of very low tumorigenicity 
in  syngeneic mice,  or (c) the  growth  of a  highly tumorigenic  in  vivo passaged 
Ehrlich ascites cell line. 
Analysis of Various Experimental Conditions Relative to the Effect of anti-mouse 
h~terferon  Globuli~ in DBA/2 Mice Injected i.p.  With FLC 
Both  745  and  3C1-8  FLC  have  been  transplanted  in  mice and  can  then  be 
passaged by further i.p. inoculation. Tumor cells multiply rapidly and form solid 
tumor masses in the mesentery and induce a tumor ascites (14). After several i.p. 
passages,  1-10  FLC constitute  1 LDs0 (14).  In  contrast,  in vitro passaged  FLC 
are considerably less tumorigenic when first inoculated i.p. than in vivo passaged 
FLC. Thus, when  105 to 106 in vitro cultivated FLC were injected i.p., few mice 
developed an  intra-abdominal  tumor, although approximately half of the mice 
developed a subcutaneous tumor (along the needle track). GRESSER  ET  AL.  2099 
However, mice injected with anti-interferon globulin and inoculated with in 
vitro cultivated FLC developed large intra-abdominal tumor masses with ascites 
similar  to  those  seen  in  DBA/2  mice  injected  with  in  vivo  passaged  FLC. 
Furthermore, anti-interferon globulin-treated mice injected with  105  in  vitro 
passaged FLC died at approximately the same time as control mice injected with 
105 in vivo passaged cells. It should be stressed that the effect of anti-interferon 
globulin on the transplantability of in vitro passaged FLC was the same for both 
interferon-sensitive (745) and interferon-resistant (3C18) FLC (Table I). 
The effect of anti-interferon globulin in altering the usual behavior of in vitro 
passaged  FLC  injected i.p.  was so pronounced that  we undertook a  series of 
experiments using these cells to define some of the experimental conditions and 
to determine whether antibody to mouse interferon was indeed the responsible 
factor. 
Injection of Various  Numbers  of FLC:  Constant  Amount  of Anti-interferon  Globu- 
lin.  Table II shows that anti-interferon globulin shortened the survival time of 
mice injected with various numbers of in vitro passaged 745 FLC compared with 
mice injected with anti-impurities globulin or left untreated. The comparison of 
the slopes  of the  regression  lines  between  mice injected with  anti-interferon 
globulin  and  anti-impurities  globulin  was  highly  significant  (t54  =  9.459,  p 
<0.001 ). 
Injection  of  Various  Dilutio~s  of Anti-Interferon  Globulin:  Constant  Number  of 
FLC.  Fig.  1  shows  the  relationship  between  the  amount  of anti-interferon 
globulin  injected and  the survival  time of DBA/2  mice injected with in  vitro 
passaged 3C1-8 FLC. The dose-response regression line was highly significant: p 
< 0.001 (coefficient of r.~0 = -0.852; t = -  11.54). Moreover, 18/18 mice injected 
with 10 ~7 or 104.7 interferon neutralizing units of antibody died (all 18 had intra- 
abdominal tumors) compared with 4/25 mice injected with 101'7 or 100.7 neutral- 
izing units or PBS with BSA (3 had subcutaneous (s.c.) tumors only and  1 had 
TABLE II 
Effect of Anti-interferon Globulin on Mice Injected with Various Numbers of 745 FLC 
Treatment 
No. of FLC injected i.p./mouse 
10  ~  104  l0  s  10  ~ 
Anti-interferon globulin 
Anti-impurities globulin 
None 
6/7*  6/7  5/7  6/7 
33.9*  45.1  59.8  60.3 
(29.4-40.0)  (39.3-52.9)  (50.3-73.7)  (54.7-67.2) 
5/7  6/7  4/7  2/7 
63.7  70.6  86.9  85.1 
(56.4-73.2)  (64.1-78.6)  (75.7-102.1)  (71.9-104.1) 
5/7  NT  NT  NT 
69.9 
(61.5-80.8) 
5-wk old female DBA/2 mice were injected with 0.2 ml of a  1:10 dilution of anti-interferon globulin 
(sheep 1-7) or anti-impurities globulin -2, 0, +7, +14 days (tumor cells were injected on day 0). 
The experiment was terminated at 118 d. 
* No. of mice dead with tumor 
Total no. of mice inoculated" 
*  Harmonic mean day of death +  SE (  ). 
NT, not tested. 2100  ANTIBODY  TO  INTERFERON  ENHANCES  TUMOR  TRANSPLANTABILITY 
75 
65 
60 
g4  (/) 
÷I 
c- 
O  •  40 
>, 
0 
"I0 
c- 
O 
•  20 
E 
._u 
8 
o  o 
¢ 
% 
sacrl  flce 
t 
% 
t 
9/9 
I  I  I 
5/8  2/8  '/8 
5.7  4.7  3.7  2.7  1.7  0.7  control 
No.  of antibody  units/injection  (log 1o) 
FIGURE  1.  Effect of injection of varying amounts of anti-interferon globulin on the survival 
of DBA/2 mice injected i.p. with 3CI-8  FLC. 5-wk-old male DBA/2 mice were injected i.p. 
with l0  s 3CI-8 cells on day 0. They received injections of 0.2 ml of anti-interferon globulin 
(sheep 1-7) i.p. on days -2, 0, +7, +14. Anti-interferon  globulin was diluted in PBS containing 
crystalline (RIA grade) BSA (Sigma)  50 vg/ml. The control group was injected on the same 
days with the same concentration of BSA in PBS. Numbers indicate the number of mice dead 
with tumor/total no. of mice inoculated. Arrows indicate SE. 
TABLE  III 
Effect on Survival of the Time of lnjection of Anti-interferon Globulin Relative to the Time of 
Tumor Cell "Injection 
No. of mice dead with tumor  Harmonic mean day of  Treatment 
Total no. of mice inoculated  death _  SE 
None  5/12  62.5  ]  t 
(58.8-66.7)1 
Anti-interferon  12/12  24.4  "1 
(-2, 0, +7, +14 days)  (23.8-25.0)~  N 
Anti-interferon  11/12  27.8  .J 
(-2 days only)  (25.6-30.3) 
Anti-interferon  12/12  40.0 
(+7, +14 days)  (37.0-43.5) 
5-6-wk old male DBA/2 mice were injected i.p. on day 0 with 105 745 cells cultivated in vitro. 0.2 
ml of a  1  : 10 dilution of anti-interferon globulin (sheep 1-7) was injected on the days as indicated. 
The experiment was terminated at 74 d. 
p <  0.001. 
NS, not significant. 
an intra-abdominal  tumor). A significant difference in the survival time was still 
obtained in mice injected with  103.7 interferon neutralizing units, compared with 
control tumor-inoculated mice. 
Time  of Injection  of Anti-interferon  Globulin  Relative  to  the  Time  of Tumor  Cell 
Injection.  In the preceding experiments, anti-interferon globulin was injected at 
-2, 0, +7, and +14 days (tumor cells injected on day 0). As can be seen in Table 
III, the effect on survival was most marked  when antibody was inoculated i.p. GRESSER  ET  AL.  2101 
TABLE  IV 
Effect of Different Preparations of Antibody to Interferon or Control Preparations on the Survival 
of DBA/2 Mice Inoculated i.p. With FLC 
Exper-  FLC  No. mice dead with tumor  Harmonic mean day 
iment  line in-  Treatment 
no.  jected  Total no. mice inoculated  of death _+ SE 
1  745  Anti-interferon glob-  9/9  27.1  "] 
ulin (sheep no. 5)  (25.9-28.4)  ! 
Normalserum glob-  5/9  70.6  "] 
ulin (sheep no. 2)  (62.6-80.8)] 
None  5/8  64.9  .a  S 
(57.5-74.5) 
2  3CI-8  Anti-interferon glob-  12/12  28.4  "] 
ulin (sheep no.  (27.1-29.9)]  NS  1-7)  ]  ] 
Anti-interferon glob-  11/11  26.3  .a 
ulin (goat DM)  (25.7-27.0) 
Normal serum glob-  10/12  57.7  -I 
ulin (goat DM)  (55.5-60.0)]  NS 
None  9/12  50.8  a 
(46.7-55.7) 
3  745  Anti-interferon glob-  4]6  33.8  "] 
ulin (sheep no.  (30.1-38.6)]  NS  1-7)  |  ] 
Anti-interferon glob-  0/8  34.5  _l 
ulin (sheep NIH)  (31.1-38.8) 
Normal serum glob-  5/8  >64  "] 
ulin (sheep NIH)  |  NS 
None  0/8  >64  1  "1 
4  3CI-8  Rabbit anti-inter-  10/10  22.7  J 
feron serum  (21.7-23.7) 
Rabbit anti-L1210  5/8  42.6  "1 
cell serum  (37.7-48.8)[  NS 
None  6/8  45.0  .] 
(41.7-49.0) 
5-wk old male or female DBA/2 mice were injected i.p. with 0.5 ml containing 105 in vitro passaged 
FLC.  Mice were injected with  0.2  ml of the various preparations on  days -2,  0, +7, and  +14 
(tumor cells were inoculated on day 0). 
In experiment 1 the globulins were diluted 1:5. 
In experiment 2 the sheep 1-7 and goat globulins were diluted 1:25 and 1:2, respectively. 
In experiment 3, sheep 1-7 and NIH globulins were diluted 1:8 and 1:3, respectively. 
In experiment 4, the rabbit sera were injected undiluted.  p < 0.001. 
before injection of 745 FLC, but a significant effect was still observed when mice 
were first inoculated with antibody 7 and  14 d after tumor cell injection. 
Specificity  of the  Effect  of Anti-mouse  Interferon  Globulin.  In  the  experiments 
described above only antibody to mouse interferon enhanced the transplantabil- 
ity of in vitro passaged FLC. No effect had been observed in mice injected with 
anti-impurities globulin or normal sheep serum globulin (Tables I and II). It was 
considered important to determine the effect of other anti-interferon and normal 
serum globulins on the survival time of DBA/2 mice injected i.p. with FLC. As 
shown in Table IV, inoculation of anti-interferon globulins from two other sheep 
(No. 5 and NIH), one goat (DM), and anti-serum  from one rabbit all increased 2102  ANTIBODY  TO  INTERFERON  ENHANCES  TUMOR  TRANSPLANTABILITY 
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FIGURE 2.  Kinetics of growth of 3CI-8 FLC tumors in the peritoneum of mice injected with 
anti-interferon globulin. 5-wk-old DBA/2 mice were injected with 0.2 ml of a  1:6 dilution of 
anti-interferon globulin  (O)  or  anti-impurities globulin  (O)  at  -1,  0,  and  +7  days  or  left 
untreated (D). On day 0 mice were injected i.p. with 2 ×  10  6 FLC as indicated by arrow. At 6 
and  13 days, 6  mice in each group were sacrificed, and the total number of FLC recovered 
from the peritoneum of each mouse was determined by colony formation in agarose. 
the percentage of tumor-bearing mice and decreased the survival time in mice 
injected with in vitro passaged FLC. In contrast, none of the control preparations 
exerted a similar effect, and there was no difference in survival time or incidence 
of transplantability of FLC between mice injected with control preparations and 
untreated mice. 
Growth  of FLC  Tumors  i~  the  Peritoneum  of Mice  Injected  with  Anti-interferon 
Globulins.  In the experiments described above injection of anti-interferon glob- 
ulin  increased  the  percentage  of mice  dying with  tumor  and  decreased  the 
survival  time.  It  was  of interest  to determine the  kinetics of growth  of FLC 
tumors in mice injected with anti-interferon globulin. 
As can be seen in Fig. 2, 6 d after inoculation of 3CL-8 FLC, 3/6 mice injected 
with anti-interferon globulin had 2  x  10  n FLC in the peritoneum and by 13 d, 
6/6 mice in this group had 10 s to 109 FLC in the peritoneum compared with 6 
mice injected with anti-impurities globulin and 6  untreated mice who had only 
104 to 10 '~ FLC in their peritoneal cavities. 
The livers and spleens of all  mice were examined microscopically for tumor 
metastases. None were seen, although in 2/6  mice treated with anti-interferon 
globulin and sacrificed at  13  d,  tumor cells  extended from the surface of the 
liver into the parenchyma. This was not observed in control mice. 
Effect of Sple~ectomy o~ the Actio~ of A~ti-inte~fero~  Globulins.  FLC harbor Friend 
leukemia virus (FLV), but the FLV present in the 745 and 3C1-8 cell lines is only 
weakly  leukemogenic as  determined  by  the  development of splenomegaly in 
DBA/2  mice  injected  with  cell-free  extracts  of  l0  s  FLC  (data  not  shown). 
Nevertheless, one might suggest on theoretical grounds that after injection of 
anti-interferon globulin, the FLV might become leukemogenic and the tumor GRESSER  ET  AL.  2103 
TABLE  V 
Effect of Anti-interferon Globulin on the Growth of FLC Tumors in Splenectomized Mice 
Splenec-  Treatment  No. of mice dead with tumor  Harmonic mean day 
tomy  Total no. of mice inoculated  of death + SE 
NO  Anti-interferon globulin  7/8  27.0  3 
(24.7-29.8)[ 
NO  Normal sheep globulin  0/8  >52  ..] 
YES  Anti-interferon globulin  8/8  22.4  q 
(22.0-22.9)] 
YES  Normal sheep globulin  5/8  35.2  _l 
(35.1-35.3) 
7-wk old male DBA/2 mice were splenectomized  or left intact.  1. wk later, all mice were injected 
with 0.2 ml ofa 1:6 dilution  of anti-interferon globulin (sheep 1-7) or normal sheep (no. 2) serum 
globulin at -1, 0, +7, +14 days. They were injected  i.p. on day 0 with 10  ~ 745 FLC cultivated  in 
vitro. The experiment was terminated at 52 d. None of the surviving mice had any gross evidence 
of tumor. 
p <  0.001. 
TABLE  VI 
Effect of Anti-interferon Globulin on the Growth of 745 FLC Tumors 
hnplanted Subcutaneously 
Harmonic mean day of death  Treatment  + SE 
Anti-interferon globulin  30.9  "] 
(29.5-32.5)  J 
Anti-impurities  globulin  47.3  7 
(43.4-51.9)]  NS 
None  46.5  _] 
(43.5-49.9) 
5-wk old female  DBA/2 mice were injected  s.c. in the dorsal area with 
0.2 ml of sheep  1-7 anti-interferon globulin diluted 1:10 or anti-impu- 
rities globulin at -2, 0, +6, +13 days. On day 0, 105 745 FLC cultivated 
in vitro were injected  s.c. at the site of globulin  injections. There were 
8 mice in each of the different groups. All mice in the different groups 
died. 
NS, Not significant. 
p <  0.001. 
ceils observed in the peritoneum  of anti-interferon  globulin  treated  mice might 
be derived  from FLV-transformed  spleen  cells.  Thus,  we determined  the effect 
of anti-interferon  globulin  on  the  transplantability  of in  vitro  passaged  FLC  in 
splenectomized  DBA/2  mice. 
As can be seen from Table V, splenectomy did not abrogate the effect of anti- 
interferon globulin on the survival time of mice injected i.p. with in vitro passaged 
745  FLC, even though splenectomy decreased the survival time of control mice 
injected with  745  FLC. 
Effect of Anti-interferon  Globulin  on the Growth of FLC Tumors Implanted s.c. 
Mice were injected s.c. with in vitro passaged 745 FLC and also injected at the 
same  time  with  either  anti-interferon  globulin  or  anti-impurities,  or  left  un- 
treated.  As can  be seen  from  Table  VI,  a  significant  difference  in  the  survival 
time  was observed  between  mice injected  with anti-interferon  globulin  and  the 
two other groups when  105 FLC were injected. 2104  ANTIBODY  TO  INTERFERON  ENHANCES  TUMOR  TRANSPLANTABILITY 
Attempts to Demonstrate the Presence of Interferon  in DBA/2 Mice Before or 
After Injection of FLC 
The presence of interferon could not be demonstrated in peritoneal washings, 
splenic extracts, or sera of normal  DBA/2 mice. In several experiments DBA/2 
were injected i.p. with varying numbers of 745 or 3C1-8 FLC passaged in vitro 
or in vivo, and peritoneal washings, splenic extracts, and sera tested at 2, 6, 24, 
48, 72, 96 hours,  1 and 2 weeks thereafter.  Interferon was not detected in any 
of the samples.  As injection of interferon enhances splenic NK cell cytotoxicity 
(16), we injected varying numbers of FLC i.p.  and determined  splenic NK cell 
cytotoxicity at intervals thereafter.  Injection of FLC i.p. did not increase splenic 
NK cell cytotoxicity. 
Cultivation  of FLC in the Presence of Anti-interferon  Globulin Does Not Alter 
Their Transplantability 
To determine  whether  anti-interferon  globulin  acted directly on  the  tumor 
cells, 745 FLC cultivated in vitro were passaged three times in the presence of a 
1 : 100 dilution of sheep 1-7 anti-interferon  globulin or anti-impurities globulin. 
DBA/2 mice were then injected i.p. with  105 cells from each group. There was 
no significant  difference in  the  mean  day of death  (or the percentage of mice 
dying) between the two groups (data not shown). 
Discussion 
The results presented herein show that injection of male and female DBA/2, 
C57BI/6, or BALB/c mice with antibody to mouse interferon enhanced the i.p. 
transplantability  of six  different  murine  tumors  (eight  tumor  cell  lines).  This 
effect was manifested  by a  pronounced  decrease in  survival time and  in  some 
instances by an increase in the percentage of tumor-bearing mice. The enhance- 
ment in transplantability was most marked when tumor cells had been previously 
passaged in  vitro and  were of low tumorigenicity  or when  only a  few in  vivo 
passaged tumor cells were injected (Table I). Thus, in vitro cultured FLC induce 
subcutaneous tumors but do not readily form tumors in the peritoneum.  How- 
ever, in mice injected with anti-interferon globulin, in vitro passaged FLC grew 
rapidly i.p.  and  formed extensive  intra-abdominal  tumors  similar  to those ob- 
served in mice injected with in vivo passaged FLC. 
Analysis of some of the experimental  conditions using FLC, showed that the 
enhancing  effect was observed over a  wide range  of tumor cell inocula (Table 
II); that  the effect was directly related to the amount of antibody to interferon 
injected (Fig.  1); and was most pronounced when antibody was administered at 
the time of tumor cell injection (Table III). An enhancing effect was also observed 
when FLC were injected s.c. Antibody to interferon did not act directly on the 
tumor cells as cultivation of FLC for three passages in the continued presence of 
anti-interferon  globulin or anti-impurities  globulin did not affect their tumori- 
genicity. 
This  ensemble  of results  raises  two  main  questions.  Is  antibody  to  mouse 
interferon responsible for the effects observed? And if so, how does it act? 
Concerning  the  specificity,  we  have  shown  that  hyperimmune  anti-mouse 
interferon  c~/fl globulins  from  three  sheep  and  one  goat  (produced  in  three GRESSER  ET  AL.  2105 
laboratories) exerted an enhancing effect on the growth of in vitro passaged FLC 
injected  i.p.  The  main  control  preparation  consisted  of the  Ig  from  a  sheep 
immunized with "impurities" present in the partially purified interferon. Neither 
this Ig nor normal sheep and goat serum globulins affected the growth of FLC. 
Crude  rabbit  anti-mouse  interferon  serum  exerted  an  effect,  whereas  crude 
serum  from  a  rabbit  immunized  against  mouse  lymphoma  L1210  cells  was 
ineffective. We conclude therefore, that antibody to mouse interferon is indeed 
responsible for the enhancement of transplantability of these tumors in mice. 
We have previously shown that administration  of interferon to mice results in 
the  inhibition  of growth  of most  of the  tumor  cells  used  in  this  study  (12) 
including the interferon-sensitive  and  interferon-resistant  L 1210 cells (17) and 
FLC (14,  18,  19). These previous results suggested the possibility that the anti- 
tumor effect of interferon  was at least in part host-mediated (17-20).  Thus,  if 
endogenous interferon  inhibits  the transplantability  of in vitro cultivated FLC, 
as our experiments with anti-interferon  globulin suggest, it is not surprising that 
the anti-interferon  globulin was equally effective in mice inoculated with inter- 
feron-sensitive and interferon-resistant  tumor cell lines (Table I). 
The most likely explanation  for the results observed would be that antibody 
against mouse interferon a/~ increased transplantability  of tumor cells because 
it  neutralized  endogenous  mouse  interferon  that  was  either  present prior to 
inoculation of tumor cells or was induced by inoculation of tumor cells. However, 
despite a variety of experimental protocols, we have been unable to demonstrate 
any biologically active interferon in the peritoneum,  sera, or splenic extracts of 
mice  before  or  after  tumor  cell  inoculation.  It  is  possible,  nevertheless  that 
biologically active interferon is present in very small amounts or that it is present 
in  some combined  form  not detectable by our  techniques.  In  previous work, 
interferon  had also not been detected in the organs of polyoma virus-infected 
mice and yet, anti-interferon  globulin markedly enhanced the disease (4).  Like- 
wise,  Reid  et  al.  (9),  demonstrated  the  marked  effects of sheep  no.  1  anti- 
interferon globulin on the growth and metastases of xenogeneic tumor cells in 
nude mice but failed to detect interferon in the mice. The authors were, however, 
able  to  show  that  injection  of tumor  cells  resulted  in  an  increase  in  NK  cell 
activity, which was presumed to be due to endogenous interferon as inoculation 
of mice  with anti-interferon  globulin abrogated  the  increased  NK cell activity 
(9).  However, we were unable to show any increase in  NK cell activity in mice 
injected with FLC. 
It is possible that the anti-interferon globulin acts because of its anti-interferon 
activity, but in some manner  other than  by neutralizing  biologically active free 
interferon.  For example,  if interferon  were bound to certain  specialized cells, 
macrophages or lymphocytes, anti-interferon  globulin might affect the function 
of these cells. 
We failed to demonstrate an effect of anti-interferon  globulin in some tumor 
systems. For example, anti-interferon  globulin enhanced the transplantability of 
in vitro passaged FLC in syngeneic but not in allogeneic mice. In some instances, 
the tumor cells were of very low tumorigenicity even in syngeneic mice (CVG 
and NS 1). Possibly, the low tumorigenicity was an inherent characteristic of these 
cells independent  of the  host response and  therefore these cells might  not be 2106  ANTIBODY  TO  INTERFERON  ENHANCES TUMOR  TRANSPLANTABILITY 
affected by any interferon-induced effect. On the other hand Ehrlich ascites cells 
multiply rapidly in  several  mouse strains and  these  cells  may be  uninfluenced 
even by interferon-enhanced host defense mechanisms. 
The point we should like to stress from these studies and those of Reid et al. 
(9) and Shouval et al.l  is that endogenous interferon appears to be an important 
factor in  inhibiting the transplantability  in  mice of some tumors,  regardless of 
their origin. These results raise the possibility that endogenous interferon may 
play some role in controlling the growth and possibly the metastases of autoch- 
thonous tumors in man. 
Summary 
Injection  of  DBA/2,  C57Bi/6,  or  BALB/c  mice  with  antibody  to  mouse 
interferon a/B enhanced the i.p. transplantability of six different murine tumors, 
as  manifested  by an  increase  in  the  percentage  of tumor-bearing  mice  and  a 
decrease in survival time. The effect was observed in mice injected with antibody 
to  interferon raised  in  three  sheep,  a  goat,  and  a  rabbit,  but  not  with  sheep 
antibody to  "impurities" present  in  the  mouse interferon preparations or with 
normal sheep or goat globulins. The enhancement in transplantability was most 
marked when tumor cells had been previously passaged in vitro and were of low 
tumorigenicity. Analysis of some of the experimental conditions using interferon- 
sensitive  and  interferon-resistant  lines  of Friend  erythroleukemia  cells  (FLC) 
showed that the enhancing effect was observed over a  wide range of tumor cell 
inocula,  was  directly related to the amount  of antibody to interferon injected 
and was most pronounced when antibody was administered at the time of tumor 
cell injection.  Enhancement was also observed when  FLC were injected subcu- 
taneously (s.c.). Antibody did not act directly on the tumor cells in vitro. Although 
we were unable to demonstrate any biologically active interferon in mice before 
or after tumor cell inoculation, the results suggest that endogenous interferon is 
present and plays a role in inhibiting the transplantability of some murine tumors 
in immunocompetent mice. 
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